We conclude that TRPV1 antagonists may represent a class of novel anti-diabetic drugs that regulate hyperglycemia and prevent weight gain by ameliorating the low-grade inflammation that is seen in diabetes and in obesity. This evidence concerns the gene TRPV1 and diabetes mellitus.